Filing Flows › Comparisons › CBIO vs PRPH
Crescent Biopharma vs ProPhase Labs: CBIO and PRPH compared
Crescent Biopharma is the larger company: $1.0M of revenue in its latest quarter (Q1 2026) against $1.0M for ProPhase Labs (Q2 2026).
Where the money goes: CBIO and PRPH
Crescent Biopharma (CBIO) · Q1 2026
Crescent Biopharma, Q1 2026: revenue $1.0M, net loss $23.3M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
ProPhase Labs (PRPH) · Q2 2026
ProPhase Labs, Q2 2026: revenue $1.0M (-19% year over year), operating margin -261.6%, net loss $3.1M, operating cash flow −$78K. The chart follows the revenue to costs, profit and cash.
| Crescent Biopharma (CBIO) | ProPhase Labs (PRPH) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $1.0M | $1.0M |
| Revenue growth, Y/Y | — | -19% |
| Operating margin | n/m | -261.6% |
| Net earnings | −$23.3M | −$3.1M |
| Net margin | — | -301.8% |
| Operating cash flow | −$8.9M | −$78K |
Questions
Which is bigger, Crescent Biopharma or ProPhase Labs?
Crescent Biopharma is the larger company: $1.0M of revenue in its latest quarter (Q1 2026) against $1.0M for ProPhase Labs (Q2 2026).
More: Crescent Biopharma earnings · how Crescent Biopharma makes money · ProPhase Labs earnings · how ProPhase Labs makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Apr 29, 2026; 10-Q filed Aug 19, 2026). Fiscal quarters can end on different dates. Not investment advice.